Early impact of 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis—Burkina Faso, 2014–2015

•Burkina Faso introduced 13-valent pneumococcal conjugate vaccine (PCV13) in 2013.•By 2015, incidence of PCV13 pneumococcal meningitis decreased by 32%.•Large decreases occurred among children aged

Saved in:
Bibliographic Details
Published in:The Journal of infection 2018-03, Vol.76 (3), p.270-279
Main Authors: Kambiré, Dinanibè, Soeters, Heidi M., Ouédraogo-Traoré, Rasmata, Medah, Isaïe, Sangaré, Lassana, Yaméogo, Issaka, Sawadogo, Guetawendé, Ouédraogo, Abdoul-Salam, Ouangraoua, Soumeya, McGee, Lesley, Srinivasan, Velusamy, Aké, Flavien, Congo-Ouédraogo, Malika, Ky Ba, Absatou, Whitney, Cynthia G., Novak, Ryan T., Van Beneden, Chris
Format: Article
Language:English
Subjects:
Adolescent
Adult
Burkina Faso
Burkina Faso - epidemiology
Child
Child, Preschool
Epidemiological Monitoring
Humans
Immunization Programs
Incidence
Infant
Meningitis
Meningitis, Pneumococcal - epidemiology
Meningitis, Pneumococcal - immunology
Meningitis, Pneumococcal - prevention & control
Pneumococcal conjugate vaccine
Pneumococcal meningitis
Pneumococcal Vaccines - administration & dosage
Pneumococcal Vaccines - immunology
Surveillance
Vaccine impact
Vaccines, Conjugate - administration & dosage
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Burkina Faso introduced 13-valent pneumococcal conjugate vaccine (PCV13) in 2013.•By 2015, incidence of PCV13 pneumococcal meningitis decreased by 32%.•Large decreases occurred among children aged
ISSN:0163-4453
1532-2742
DOI:10.1016/j.jinf.2017.12.002